Moody National Bank Trust Division’s BioMarin Pharmaceuticals BMRN Stock Holding History

Moody National Bank Trust Division’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,752	Closed	-$509K	–	512
2023 Q3	$509K	Buy	5,752 +2,069	+56%	+$184K	0.03%	377
2023 Q2	$319K	Buy	3,683 +154	+4%	+$14.5K	0.02%	490
2023 Q1	$343K	Sell	3,529 -10	-0.3%	-$1.04K	0.03%	470
2022 Q4	$367K	Sell	3,539 -12	-0.3%	-$1.13K	0.03%	436
2022 Q3	$301K	Hold	3,551	–	–	0.03%	461
2022 Q2	$294K	Sell	3,551 -3,425	-49%	-$273K	0.03%	412
2022 Q1	$538K	Sell	6,976 -945	-12%	-$79.1K	0.02%	268
2021 Q4	$700K	Sell	7,921 -21,651	-73%	-$1.79M	0.02%	252
2021 Q3	$2.29M	Sell	29,572 -40	-0.1%	-$3.16K	0.03%	221
2021 Q2	$2.47M	Sell	29,612 -50	-0.2%	-$3.96K	0.05%	220
2021 Q1	$2.24M	Sell	29,662 -28	-0.1%	-$2.29K	0.05%	220
2020 Q4	$2.6M	Sell	29,690 -80	-0.3%	-$6.34K	0.07%	203
2020 Q3	$2.27M	Hold	29,770	–	–	0.07%	193
2020 Q2	$3.67M	Hold	29,770	–	–	0.11%	147
2020 Q1	$2.52M	Hold	29,770	–	–	0.09%	160
2019 Q4	$2.52M	Hold	29,770	–	–	0.07%	182
2019 Q3	$2.01M	Hold	29,770	–	–	0.06%	191
2019 Q2	$2.55M	Hold	29,770	–	–	0.07%	180
2019 Q1	$2.65M	Sell	29,770 -10	-0%	-$927	0.07%	179
2018 Q4	$2.54M	Hold	29,780	–	–	0.07%	168
2018 Q3	$2.89M	Buy	29,780 +26,555	+823%	+$2.65M	0.07%	168
2018 Q2	$304K	Hold	3,225	–	–	0.01%	221
2018 Q1	$262K	Sell	3,225 -65	-2%	-$5.58K	0.01%	230
2017 Q4	$293K	Hold	3,290	–	–	0.01%	227
2017 Q3	$306K	Sell	3,290 -940	-22%	-$83.1K	0.02%	216
2017 Q2	$384K	Hold	4,230	–	–	0.02%	211
2017 Q1	$371K	Hold	4,230	–	–	0.02%	212
2016 Q4	$350K	Hold	4,230	–	–	0.02%	211
2016 Q3	$391K	Hold	4,230	–	–	0.02%	188
2016 Q2	$329K	Hold	4,230	–	–	0.02%	213
2016 Q1	$349K	Hold	4,230	–	–	0.02%	191
2015 Q4	$443K	Buy	+4,230	New	+$442K	0.03%	155

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Moody National Bank Trust Division's BMRN Position: Q4 2023 in Review

Moody National Bank Trust Division sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 5,752 shares — an estimated $509K sold.

Moody National Bank Trust Division first reported a position in BMRN in Q4 2015 and held it in 32 quarters. The position peaked at $3.67M in Q2 2020. 548 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

Moody National Bank Trust Division reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Moody National Bank Trust Division sold 5,752 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $509K.
Moody National Bank Trust Division first reported a position in BioMarin Pharmaceuticals in Q4 2015 and held it in 32 quarters.
Moody National Bank Trust Division's BioMarin Pharmaceuticals position peaked at $3.67M in Q2 2020.
548 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on Moody National Bank Trust Division's 13F filing for Q4 2023, filed 11 Jan 2024.